In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 609-618

  Raungrut, Pritsana ^a,b   Uchaipichat, Verawan ^a,c   Elliot, David J ^a   Janchawee, Benjamas ^b   Somogyi, Andrew A ^d   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CODEINE 6 GLUCURONIDE; DEXTROPROPOXYPHENE; FLUCONAZOLE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; KETOCONAZOLE; METHADONE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VALPROIC ACID;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG SCREENING; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MICHAELIS CONSTANT; PREDICTION; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ANIMALS; CATTLE; CODEINE; DEXTROPROPOXYPHENE; DRUG INTERACTIONS; FLUCONAZOLE; GLUCURONOSYLTRANSFERASE; HUMANS; KETOCONAZOLE; METHADONE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; SERUM ALBUMIN, BOVINE;

EID: 77954896503     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167916     Document Type: Article

References (44)

1. Badcock NR, Bartholomeusz FD, Frewin DB, Sansom LN, and Reid JG (1987) The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol 33:531-534. (Pubitemid 18017558)
2. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
3. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
4. Bourcier K, Hyland R, Kempshall S, Jones R, Maximilien J, Irvine N and Jones B (2010) Investigation into UDP-glucuronosyltransferase enzyme kinetics of imidazole and triazole containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos 38:923-929.
5. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
6. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
7. Chen ZR, Somogyi AA, Reynolds G, and Bochner F (1991) Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 31:381-390.
8. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
9. Daneshmend TK and Warnock DW (1988) Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14:13-34.
10. Foster DJ, Somogyi AA, White JM, and Bochner F (2004) Population pharmacokinetics of (R)-, (S)-, and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57:742-755.
11. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, and Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827-2831.
12. Giacomini KM, Gibson TP, and Levy G (1978) Plasma protein binding of D-propoxyphene in normal and anephric patients. J Clin Pharmacol 18:106-109.
13. Gram LF, Schou J, Way WL, Heltberg J, and Bodin NO (1979) D-Propoxyphene kinetics after single and oral intravenous doses in man. Clin Pharmacol Ther 26:473-482. (Pubitemid 10214572)
14. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, and Foley KM (1987) Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 41:392-401. (Pubitemid 17058923)
15. Inturrisi CE, Colburn WA, Verebey K, Dayton HE, Woody GE, and O'Brien CP (1982) Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther 31:157-167.
16. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
17. Jin CJ, Mackenzie PI, and Miners JO (1997) The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 341:207-211.
18. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, and Miners JO (2009) Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltrannsferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos 37:1948-1955.
19. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
20. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, and Koren G (2009) Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 85:31-35.
21. McCance-Katz EF, Rainey PM, Jatlow P, and Friedland G (1998) Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 18:435-443.
22. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
23. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
24. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug glucuronidation parameters in humans: UDP-glucuronosyltransferase enzymeselective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:189-201.
25. Morrish GA, Foster DJ, and Somogyi AA (2005) Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. Br J Clin Pharmacol 61:326-335.
26. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDPglucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
27. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008a) The albumin effect and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870-877.
28. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
29. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147.
30. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008b) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062.
31. Sahai J, Gallicano K, Pakuts A, and Cameron DW (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 169:1103-1107. (Pubitemid 24303236)
32. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, pp 104 and 129, J. Wiley and Sons, New York.
33. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
34. Somogyi AA, Barratt DT, and Coller JK (2007) Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429-444.
35. Somogyi AA, Gelston E, Coller JK, White JM, and Schmidt H (2009) Methadone inhibits CYP2D6 and UGT2B7 in vivo: a study using codeine as the substrate. Drug Metab Rev 41(Suppl 1):45-46.
36. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, and Yamada H (2006) Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34:1277-1282.
37. Thorn CF, Klein TE, and Altman RB (2009) Codeine and morphine pathway. Pharmacogenet Genomics 19:556-558.
38. Trapnell CB, Klecker RW, Jamis-Dow C, and Collins JM (1998) Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 42:1592-1596.
39. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006a) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
40. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
41. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006b) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
42. Welling PG, Lyons LL, Tse FL, and Craig WA (1976) Propoxyphene and norpropoxyphene: influence of diet and and fluid on plasma levels. Clin Pharmacol Ther 19:559-565.
43. Yong WP, Ramirez J, Innocenti F, and Ratain MJ (2005) Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 11:6699-6704.
44. Yue QY, Hasselström J, Svensson JO, and Säwe J (1991) Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 31:635-642.